KIR3DL1 and follicular lymphoma: Our in vitro data were recently confirmed by the analysis of follicular lymphoma patients treated with rituximab, which showed that progression-free survival (PFS) decreases with the number of viable KIR/HLA interactions.3 These data indicate a need for strategies to overcome the negative impact of KIR/HLA interactions in order to enhance the efficacy of therapeutic antibodies.